← Leaderboards
Richard Thomas Maziarz
Oregon Health & Science University
$1,598,563
Attributed
$1,598,563
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $244K · FY2017–25$250K$187.5K$125K$62.5K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,598,563 · 2
By mechanism
UG1$1,598,563 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Molecular”
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Lynn Briscoe · Leidos Biomedical Research, Inc.$137,360,557
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$109,548,439
- Leonard Freedmand · Leidos Biomedical Research, Inc.$85,594,314
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
- Scott Hensley · University Of Pennsylvania$41,662,743
Research focus
MolecularMorphologyHigh RiskGenomicsIn Complete RemissionMemberCytogeneticsEffectivenessConditioningFluorescent In Situ HybridizationDna SequencingHomologous TransplantationInvestigationInstitutionAcute Myelocytic LeukemiaCollaborationsDisease RemissionChemotherapyBiologyComorbidityFailureFlow CytometryAllogenicMortality
Grant awards (8)
BMT Core - Oregon Health and Science University (OHSU) Consortium$228,000
UG1 · FY2025 · HL · contact PI
BMT Core - Oregon Health and Science University (OHSU) Consortium$244,000
UG1 · FY2024 · HL · contact PI
Novel Strategies for Assessing and Optimizing Therapy for Minimal Residual Disease after Allogeneic Transplantation for AML and MDS$186,595
UG1 · FY2022 · HL · contact PI
Novel Strategies for Assessing and Optimizing Therapy for Minimal Residual Disease after Allogeneic Transplantation for AML and MDS$186,595
UG1 · FY2021 · HL · contact PI
Novel Strategies for Assessing and Optimizing Therapy for Minimal Residual Disease after Allogeneic Transplantation for AML and MDS$186,595
UG1 · FY2020 · HL · contact PI
Novel Strategies for Assessing and Optimizing Therapy for Minimal Residual Disease after Allogeneic Transplantation for AML and MDS$186,595
UG1 · FY2019 · HL · contact PI
Novel Strategies for Assessing and Optimizing Therapy for Minimal Residual Disease after Allogeneic Transplantation for AML and MDS$177,267
UG1 · FY2018 · HL · contact PI
Novel Strategies for Assessing and Optimizing Therapy for Minimal Residual Disease after Allogeneic Transplantation for AML and MDS$202,916
UG1 · FY2017 · HL · contact PI